Company to advance M107 into Phase 2 clinical development in gastroparesis based on feedback from Pre-IND meeting with FDARADNOR, Pa. (BUSINESS WIRE) Aclipse Therapeutics, and its subsidiary, Aclipse Two, Inc (“Aclipse”), an innovative biopharmaceutical company developing life-changing treatments for patients with.
New £1.2 million funding to advance development of investigational MND drug miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
£1.6 million grant awarded to advance development of MND drug candidate
Researchers from the University of Sheffield s Institute for Translational Neuroscience (SITraN) have been awarded a £1.6 million grant from the Medical Research Council (MRC). The grant will support their partnership with Aclipse Therapeutics to advance the translational development of M102 - a drug candidate for the treatment of motor neuron disease (MND).
Neuroprotective properties of M102 were discovered by SITraN researchers in 2013. Preclinical models evidenced the potential for M102 to slow down MND progression, which affects a patient s ability to walk, talk, eat and breathe.
The drug candidate activates the NRF2 (nuclear factor erythroid 2-related factor 2) and HSF1 (Heat shock factor 1) signalling pathways, which can work in combination to protect motor neurons from injury.
E-Mail
M102 is a disease-modifying drug candidate for motor neuron disease (MND) that was discovered by Sheffield scientists in 2013
University of Sheffield partnership with Aclipse Therapeutics awarded a £1.6m grant by the Medical Research Council (MRC) to advance the translational development of M102
MRC grant follows funding from FightMND to take M102 into clinical trials with patients
MND - also known as Amyotrophic Lateral Sclerosis (ALS) - is a devastating disease that affects 5,000 people in the UK and 450,000 people worldwide
Researchers from the University of Sheffield s Institute for Translational Neuroscience (SITraN) have been awarded a £1.6 million grant from the Medical Research Council (MRC). The grant will support their partnership with Aclipse Therapeutics to advance the translational development of M102 - a drug candidate for the treatment of motor neuron disease (MND).